Patenting Trends by Mexican Pharmaceutical Companies

References

• Alshrari AS , Hudu SA , Imran M et al. Innovations and development of COVID-19 vaccines: a patent review. J. Infect. Public Health. 15(1), 123–131 (2022).
   PubMed Web of Science ®Google Scholar
• Burrell R , Kelly C . The COVID-19 pandemic and the challenge for innovation policy. N. Ir. Legal Q. 71, 89 (2020).
   Google Scholar
• Bonadio E , Baldini A . COVID-19, patents and the never-ending tension between proprietary rights and the protection of public health. Eur. J. Risk Regul. 11(2), 390–395 (2020).
   Web of Science ®Google Scholar
• Demir E , Bican PM . Patents and Sustainable Medical Treatment in Developing Countries: Lessons from COVID-19 Vaccines. Sustainability. 15(4), 3121 (2023).
   Web of Science ®Google Scholar
• Altindis E . Inequitable COVID-19 vaccine distribution and the intellectual property rights prolong the pandemic. Expert Rev Vaccines. 21(4), 427–430 (2022).
   PubMed Web of Science ®Google Scholar
• Salikhova O . Ukraine’s pharmaceuticals: from dependence to endogenous development. Econ Forecast. (4), 5–33 (2020).
   Google Scholar
• Wang S , Liu Q , Chen Y . Independent research and development, technology accumulation and innovation performance: evidence from China’s pharmaceutical manufacturing industry. PLoS ONE 17(4), e0266768 (2022).
   PubMed Web of Science ®Google Scholar
• Okuyama R . Strengthening the Competitiveness of Japan’s Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan’s Highly Productive Firm. Biol. Pharm. Bull. 46(5), 718–724 (2023).
   PubMed Web of Science ®Google Scholar
• Hassanin ME , Hamada MA . A Big Data strategy to reinforce self-sustainability for pharmaceutical companies in the digital transformation era: a case study of Egyptian pharmaceutical companies. African J. Sci, Technol, Innov. Dev. 14(7), 1870–1882 (2022).
   Web of Science ®Google Scholar
• Cherian JJ , Rahi M , Singh S et al. India’s road to independence in manufacturing active pharmaceutical ingredients: focus on essential medicines. Economies 9(2), 71 (2021).
   Web of Science ®Google Scholar
• González-Ramírez R , Castañeda-Hernández G . The challenges of developing and commercializing biosimilars in Latin America. Pharm. Pat. Anal. 8(6), 221–224 (2019).
   PubMed Web of Science ®Google Scholar
• Ortiz-Prado E , Ponce-Zea J , Vasconez JE et al. Current trends for biosimilars in the Latin American market. Generics and Biosimilars Initiative J. 9(2), 64–74 (2020).
   Google Scholar
• Ortiz-Prado E , Espín E , Vásconez J et al. Vaccine market and production capabilities in the Americas. Trop. Dis. Travel Med. Vaccines. 7, 1–21 (2021).
   PubMedGoogle Scholar
• Sanchez-Esgua G , Reyes-Alvarez J , Perez-Santos M . Patenting trends in the pharmaceutical field of Mexican universities. Pharm. Pat. Anal. 12(1), 37–50 (2023).
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzalez A , Gonzalez-Fierro A . Barriers for pharmaceutical innovation with focus in cancer drugs, the case of Mexico. Ther. Innov. Regul. Sci. 54, 342–352 (2020).
   PubMed Web of Science ®Google Scholar
• Psicofarma . MX270322 (2009).
   Google Scholar
• Gonzalez-Fierro A , Vasquez-Bahena D , Taja-Chayeb L et al. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. Intern. J. Clin. Pharmacol. Ther. 49(8), 519 (2011).
   PubMed Web of Science ®Google Scholar
• Laboratorios Senosiain . MX333916 (2015).
   Google Scholar
• Landsteiner Scientific . MX358211 (2018).
   Google Scholar
• Johnson R , Dludla P , Mabhida S et al. Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review. Heart Fail. Rev. 24(3), 343–357 (2019).
   PubMed Web of Science ®Google Scholar
• Laboratorios Silanes . MX248617 (2007).
   Google Scholar
• Laboratorios Silanes . MX310386 (2013).
   Google Scholar
• Laboratorios Silanes . MX317132 (2014).
   Google Scholar
• Albetawi S , Abdalhafez A , Abu-Zaid A . A review on recent controlled release strategies for oral drug delivery of repaglinide (a BCS Class II Drug). Pharm. Nanotechnol. 9(5), 326–338 (2021).
   PubMedGoogle Scholar
• Alparis . MX389619 (2022).
   Google Scholar
• Alparis . MX395846 (2022).
   Google Scholar
• Kumar S , Mittal A , Mittal A . A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. Bioorg. Med. Chem. 46, 116354 (2021).
   PubMed Web of Science ®Google Scholar
• Alparis . MX379913 (2021).
   Google Scholar
• Cell Therapy and Technology. MX366086 (2019).
   Google Scholar
• Medix . MX394208 (2022).
   Google Scholar
• Laboratorios Senosiain . MX288292 (2011).
   Google Scholar
• Laboratorios Senosiain . MX292943 (2011).
   Google Scholar
• Laboratorios Senosiain . MX324739 (2014).
   Google Scholar
• Laboratorios Senosiain . MX291185 (2011).
   Google Scholar
• Laboratorios Senosiain . MX333915 (2015).
   Google Scholar
• Laboratorios Senosiain . MX331968 (2015).
   Google Scholar
• Laboratorios Senosiain . MX320915 (2014).
   Google Scholar
• Liomont . MX377759 (2020).
   Google Scholar
• Psicofarma . MX321510 (2014).
   Google Scholar
• Alparis . MX379504 (2021).
   Google Scholar
• Alparis . MX2018004788 (2021).
   Google Scholar
• Alparis . MX264977 (2009).
   Google Scholar
• RIMSA . MX283340 (2011).
   Google Scholar
• RIMSA . MX304321 (2012).
   Google Scholar
• Senosiain . MX282576 (2011).
   Google Scholar
• Senosiain . MX320916 (2014).
   Google Scholar
• Senosiain . MX357376 (2018).
   Google Scholar
• Senosiain . MX343106 (2016).
   Google Scholar
• Senosiain . MX268712 (2009).
   Google Scholar
• Senosiain . MX282883 (2012).
   Google Scholar
• Senosiain . MX328072 (2015).
   Google Scholar
• Senosiain . MX328280 (2015).
   Google Scholar
• Raam de Sahuayo . MX348595 (2017).
   Google Scholar
• Raam de Sahuayo . MX362435 (2019).
   Google Scholar
• Raam de Sahuayo . MX388067 (2020).
   Google Scholar
• Raam de Sahuayo . MX393662 (2022).
   Google Scholar
• Raam de Sahuayo . MX389850 (2022).
   Google Scholar
• Raam de Sahuayo . MX384760 (2022).
   Google Scholar
• Rayere . MX267736 (2009).
   Google Scholar
• Rayere . MX275811 (2010).
   Google Scholar
• Rayere . MX274569 (2010).
   Google Scholar
• Rayere . MX279629 (2010).
   Google Scholar
• Rayere . MX351622 (2017).
   Google Scholar
• Rayere . MX344937 (2017).
   Google Scholar
• von Delft A , Hall MD , Kwong AD et al. Accelerating antiviral drug discovery: lessons from COVID-19. Nat. Rev. Drug Discov. 22(7), 585–603 (2023).
   PubMed Web of Science ®Google Scholar
• Palmer M , Chaguturu R . Academia–pharma partnerships for novel drug discovery: essential or nice to have? Expert Opin. Drug Discov. 12(6), 537–540 (2017).
   PubMed Web of Science ®Google Scholar
• Cid-Uribe JI , Veytia-Bucheli JI , Romero-Gutierrez T . Scorpion venomics: a 2019 overview. Expert Rev. Proteomics 17(1), 67–83 (2020).
   PubMed Web of Science ®Google Scholar
• Restano-Cassulini R , Garcia W , Paniagua-Solís JF , Possani LD . Antivenom evaluation by electrophysiological analysis. Toxins 9(3), 74 (2017).
   PubMed Web of Science ®Google Scholar
• Riaño-Umbarila L , Gómez-Ramírez IV , Ledezma-Candanoza LM , Olamendi-Portugal T et al. Generation of a broadly cross-neutralizing antibody fragment against several Mexican scorpion venoms. Toxins 11(1), 32 (2019).
   PubMed Web of Science ®Google Scholar
• Psicofarma . MX270322 (2009).
   Google Scholar
• Espinoza-Zamora JR , Labardini-Méndez J , Sosa-Espinoza A . Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study. Expert Opin. Investig. Drugs 26(4), 481–487 (2017).
   PubMed Web of Science ®Google Scholar
• Candelaria M , Burgos S , Ponce M . Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS). Ann. Hematol. 96(11), 1825–1832 (2017).
   PubMed Web of Science ®Google Scholar
• Torres Vargas A , Jasso Villazul J . Capabilities and knowledge transfer: evidence from a university research center in the health area in Mexico. Contaduría y administración. 64(SPE1), 10.22201/fca.24488410e.2019.1808 (2019).
   Google Scholar
• Soto Rubio M , Germán-Soto V , Gutiérrez Flores L . Patentes, tamaño de empresa y financiamiento público en México: análisis regional con modelos de datos de conteo. Mexican J. Econ. Finance 18(1), (2023).
   Google Scholar
• Solleiro-Rebolledo JL , Castañón-Ibarra R , Martínez-Salvador LE . Análisis y prospectiva de la política de ciencia, tecnología e innovación en México. Iuris Tantum. 33(30), 285–308 (2019).
   Google Scholar
• Ponce Jaramillo IE , Guemes Castorena D . Identification of key factors of academia in the process of linking in the triple helix of innovation model in Mexico, a state of the art matrix. Nova Scientia 8(16), 246–277 (2016).
   Google Scholar
• Guzmán A , Acatitla E , Vázquez T . Propensity toward industry-science links across Mexico’s technological sectors: an analysis of patents, 1980-2013. EconoQuantum. 13(1), 125–157 (2016).
   Google Scholar